New cancer vaccine targets 'Undruggable' KRAS mutations in early trial
NCT ID NCT04853017
Summary
This early-stage trial tested a new immunotherapy called ELI-002 in 25 people with pancreatic, colorectal, lung, and other cancers that have specific KRAS mutations. The treatment was given after standard therapy to target any remaining cancer cells and prevent recurrence. Researchers primarily wanted to see if the treatment was safe and if it could reduce cancer markers in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Northwell Health
Lake Success, New York, 11042, United States
-
Tennessee Oncology - Centennial Clinic
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.